Pharmaceutical

Drug Farm candidate gains rare paediatric disease status  

Drug Farm’s ALPK1 inhibitor DF-003 is being investigated in a Phase I trial for the treatment of ROSAH, enrolling 96 healthy subjects.

Jan 15, 2024 - 18:00
Drug Farm candidate gains rare paediatric disease status  
Drug Farm’s ALPK1 inhibitor DF-003 is being investigated in a Phase I trial for the treatment of ROSAH, enrolling 96 healthy subjects.
Read the original article

Tags:

Previous Article

Opinion: What STAT readers think about JPM’s locked lactation room, covering wei...

Next Article

Amgen showcases exciting potential in the obesity space at JPM24

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Arcus Biosciences obtains loan facility with Hercules Capital worth $250m

Arcus Biosciences obtains loan facility with Hercules C...

Aug 29, 2024

STAT+: FDA cracks down on websites that claim to sell chemicals in obesity drugs Wegovy, Zepbound

STAT+: FDA cracks down on websites that claim to sell c...

Feb 15, 2024

Sudo secures additional funds to advance TYK2 inhibitors to clinic

Sudo secures additional funds to advance TYK2 inhibitor...

Feb 14, 2024